DNMT3A and mantle cell lymphoma: Importantly, activation of the OXPHOS pathway was identified as a driver of acquired ibrutinib resistance in MCL, and DNA methyl-transferase 3A (DNMT3A) was found to act as a mediator of mitochondrial biogenesis, which is required for OXPHOS activation in MCL.